Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicera Therapeutics ABFRA:8E8 +2.70%24 EV-to-EBIT is -7.25 as of Sep. 05, 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 368 Biotechnology companies, Elicera Therapeutics AB ranks worse than 271738.86% on this metric.
Elicera Therapeutics AB (FRA:8E8) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Elicera Therapeutics AB's Enterprise Value for the quarter that ended in Jun. 2026 was €7.86 Mil.
Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicera Therapeutics AB EV-to-EBIT Related Terms
Elicera Therapeutics AB EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8E8 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Elicera Therapeutics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicera Therapeutics AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Elicera Therapeutics AB's EV-to-EBIT falls into.
Elicera Therapeutics AB's current Enterprise Value is €12.09 Mil.
Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicera Therapeutics AB (FRA:8E8) has a EV-to-EBIT of -7.25 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 368 companies in the Biotechnology industry.
Is Elicera Therapeutics AB's EV-to-EBIT too high?
Elicera Therapeutics AB's current EV-to-EBIT is -7.25. Based on the distribution chart, Elicera Therapeutics AB ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 368 companies for EV-to-EBIT. This places Elicera Therapeutics AB in the lower half of its industry. The industry median EV-to-EBIT is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elicera Therapeutics AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current EV-to-EBIT is -7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current EV-to-EBIT of -7.25. The current EV-to-EBIT is -7.25. Elicera Therapeutics AB's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current EV-to-EBIT is -7.25 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
24GF Score
Get the complete analysis for FRA:8E8
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8E8 has been successfully added to your 
